Coherus Biosciences's total assets for Q3 2024 were $505.00M, a decrease of -25.17% from the previous quarter. CHRS total liabilities were $592.97M for the fiscal quarter, a -21.87% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.